IP Library › Granted Patent US 8,470,882
Granted Patent B2
US 8,470,882 · App. 12/260,534 · Granted Jun 25, 2013

Amino acid salts of prostaglandins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,470,882
App. No.
12/260,534
Granted
Jun 25, 2013
Kind
B2
Abstract

The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

Claims (11)

1. An amino acid prostaglandin free acid salt, wherein the amino acid is arginine; and wherein the prostaglandin free acid is selected from the group consisting of travoprost free acid, fluprostenol free acid, tafluprost free acid, and bimatoprost free acid, and wherein the free acid salt is crystalline.

2. The salt according to claim 1 , wherein the prostaglandin free acid is travoprost free acid.

3. The salt according to claim 1 , wherein the prostaglandin free acid is fluprostenol free acid.

4. The salt according to claim 1 , wherein the prostaglandin free acid is tafluprost free acid.

5. The salt according to claim 1 , wherein the prostaglandin free acid is bimatoprost free acid.

6. A pharmaceutical composition comprising a salt according to claim 1 and a pharmaceutically acceptable carrier.

7. A method of treating glaucoma comprising administering to a subject in need thereof an effective amount of a salt according to claim 1 .

8. A method of improving nasal patency or treating neurogenic bladder comprising administering to a subject in need thereof an effective amount of a salt according to claim 1 .

9. A method of treating osteoporosis comprising administering to a subject in need thereof an effective amount of a salt according to claim 1 .

10. A method of reducing ocular pressure comprising contacting a cell with an amount of a salt according to claim 1 effective to reduce ocular pressure.

11. The method of claim 10 , wherein the cell is in a subject.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 25, 2016
From: ACP IV, L.P.
To: NOVAER HOLDINGS, INC.
Reel/Frame 038809/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2013
From: AERIE PHARMACEUTICALS, INC.
To: NOVAER HOLDINGS, INC.
Reel/Frame 030423/0232 →
SECURITY AGREEMENT Recorded Mar 4, 2009
From: AERIE PHARMACEUTICALS, INC.
To: ACP IV, LP, (AS COLLATERAL AGENT)
Reel/Frame 022368/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2009
From: DELONG, MITCHELL A.; STURDIVANT, JILL MARIE
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 022121/0989 →